Digestive system neuroendocrine neoplasm
Therapeutic area
Gastroenterology
Rare disease
Yes
- Definition
- A neoplasm with neuroendocrine differentiation arising from the digestive system. It includes neuroendocrine tumors (well-differentiated endocrine tumors or carcinoid tumors and well differentiated endocrine carcinomas) and neuroendocrine carcinomas (poorly differentiated neuroendocrine carcinomas, small cell carcinomas, and large cell neuroendocrine carcinomas).
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Digestive system neuroendocrine neoplasm
- Therapeutic area
- Gastroenterology
- digestive system neuroendocrine neoplasm
- alimentary part of gastrointestinal system NET
- alimentary part of gastrointestinal system neuroendocrine neoplasm
- alimentary part of gastrointestinal system neuroendocrine tumor
- alimentary part of gastrointestinal system neuroendocrine tumor, well differentiated, low or intermediate grade
- alimentary part of gastrointestinal system neuroendocrine tumour
- carcinoid tumor of digestive system
- carcinoid tumour of digestive system
- digestive system NET
- digestive system neuroendocrine tumor
- digestive system neuroendocrine tumor, well differentiated, low or intermediate grade
- digestive system neuroendocrine tumour
- gastro-enteropancreatic neuroendocrine tumor
- gastro-enteropancreatic neuroendocrine tumour
- gastroenteropancreatic endocrine tumor
- gastroenteropancreatic endocrine tumour
- gastroenteropancreatic neuroendocrine neoplasm
- gastrointestinal neuroendocrine neoplasm
- gastrointestinal system neuroendocrine neoplasm
- neuroendocrine neoplasm of alimentary part of gastrointestinal system
- neuroendocrine neoplasm of digestive system
- carcinoid tumor
- carcinoid tumour
- GEP tumors
- GEP tumours
- Severity
- Moderate
- Endocrinology
- Gastroenterology
- Oncology
Sources for recorded values
- MONDO ID
- MONDO:0024503
- Parent condition
- MONDO:0004335
Related records
Broader conditions (12)
- Cancer or benign tumor
- Digestive system disorder
- Digestive system neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Endocrine gland neoplasm
- Endocrine system disorder
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Neuroendocrine neoplasm
Narrower conditions (79)
- Ampulla of vater small cell neuroendocrine carcinoma
- Anal canal neuroendocrine neoplasm
- Appendix L-cell glucagon-like peptide-producing neuroendocrine tumor
- Appendix neuroendocrine neoplasm
- Appendix neuroendocrine tumor G1
- Ascending colon neuroendocrine tumor G1
- Cecum neuroendocrine tumor G1
- Classic neuroendocrine tumor of appendix
- Colon neuroendocrine neoplasm
- Colon neuroendocrine tumor G1
- Colon small cell neuroendocrine carcinoma
- Colonic L-cell glucagon-like peptide producing tumor
- Colorectal neuroendocrine tumor G1
- Digestive system neuroendocrine tumor, grade 1/2
- Duodenal gastrin-producing neuroendocrine tumor
- Duodenal neuroendocrine neoplasm
- Duodenal neuroendocrine tumor, well differentiated, low or intermediate grade
- Duodenal somatostatinoma
- Enterochromaffin cell serotonin-producing pancreatic neuroendocrine tumor
- Esophageal neuroendocrine tumor
Trials (87)
- [68 Ga]-DOTANOC PET/CT in GEP-NETs
- 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
- 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
- 211At-MABG in Adults With Advanced Neuroendocrine Cancers
- 68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours
- 68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET
- 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
- A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors
- A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
- A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
- A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
- A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
- A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany
- A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
- A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
- A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly
- A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
- Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
Approved drugs (1)
- Interferon alfa-2B
Drugs in development (29)
- Bevacizumab Phase 2
- Carboplatin Phase 2
- Catequentinib Phase 2
- Copper oxodotreotide CU-64 Phase 2
- Edotreotide Phase 3
- Edotreotide gallium GA-68 Phase 1
- Etoposide Phase 2
- Everolimus Phase 3
- Famitinib Phase 2
- Filgrastim Phase 2
- Fludeoxyglucose F 18 Phase 2
- Fluorouracil Phase 2
- Ipilimumab Phase 2
- Irinotecan Phase 1
- Irinotecan hydrochloride Phase 2
- Lanreotide Phase 3
- Leucovorin calcium Phase 2
- Lurbinectedin Phase 1
- Lutetium oxodotreotide LU-177 Phase 3
- Nivolumab Phase 2